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CHAPTER 1
BACKGROUND
The goal of this capstone is to highlight the use of publicly available complex sample public
health data like the National Health and Nutrition Examination Survey (NHANES) and the
Behavioral Risk Factor Surveillance System (BRFSS) to address relevant public health questions
in the topics of environmental health and health policy using epidemiologic methods.
The role of the first paper on environmental health is to assess the role of blood
manganese levels on myocardial infarction, stroke, and renal dysfunction and explore differences
based on socioeconomic status. This paper will quantify the association of blood manganese
levels and also provide information on individual and socioeconomic factors that are related to
myocardial infarction, stroke, and renal dysfunction. Due to the lack of US studies this, the
present analyses will fill some of the knowledge gaps from previous studies that were primarily
conducted in Asia and Europe.
The second paper using the health policy perspective will describe the impact of the
Affordable Care Act (2010) on current smoking and quit-attempts among expanded and nonexpanded US states, and identify the impact among low-income individuals, and examine the
state-level barriers to smoking cessation services in the expanded and non-expanded states.
The capstone will be divided into two separate papers that will include the introduction,
methods, results, discussion sections of the two distinct topics of environmental health and health
policy. Lastly, the conclusion will highlight the recommendations and the public health
implications for the two papers.
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ABSTRACT
Introduction: Manganese is an essential trace element that can cause adverse health effects with
deficiency and in excess amounts. The purpose of this study is to determine the asscociation of
blood manganese levels and the prevalence of myocardial infarction, stroke, and renal
dysfunction in a general US population.
Methods: Data were used from the National Health and Nutritional Examination Survey
(NHANES) of non-institutionalized US adults 20 years and older using the 2011-2012, 20132014, and 2015-2016 survey cycles (n=16629). Weighted multivariable logistic regression
models adjusted for age, race/ethnicity, sex, and poverty income ratio (PIR), were used to
determine the association of blood manganese levels and myocardial infarction, stroke, and renal
dysfunction accounting for the complex sample survey design.
Results: The mean and standard errors (SEs) of blood manganese levels for myocardial
infarction were [10.2 (0.4) µg/L], stroke [9.6 (0.2) µg/L], and renal dysfunction [9.4 (0.1) µg/L]
for the combined six years. In the adjusted models, the odds of myocardial infarction [odds ratio
(OR) 1.20 (95% CI: 0.76-1.90)] were highest in the highest quartile (Q4: ≥11.3 µg/L) compared
to the lower quartile (Q1: ≤7.36 µg/L). There was a non-signicant 17% increased odds of stroke
1.17 (95% CI: 0.72-1.92) comparing the highest quartile (Q4) to the lowest quartile (Q1). There
was a non-significant decreased odds of renal dysfunction 0.80 (95% CI: 0.62-1.05) in the
highest quartile (Q4) compared to the lowest quartile (Q1).
Conclusion: The increasing odds for stroke and myocardial infarction based on the manganese
quartiles, suggests that increased blood manganese levels may play an important role in the
disease process.
2
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CHAPTER 2
INTRODUCTION

Metals are abundant in the environment and their presence can be measured from many body
compartments like whole blood, serum, plasma, urine, hair, and toenails for epidemiological
studies.1 Most of the metals are essential but they can also give rise to adverse effects if their
levels increase in the body. If they accumulate for an extended period they can be toxic to
humans particularly in the young and the elderly.2-5 One of those essential elements is
manganese (Mn), which the human body is introduced via food and water consumption.6
Additionally, Mn is involved in many cellular functions like synthesis and activation of enzymes.
After it is absorbed from the gastrointestinal tract, it is transported to mitochondria rich organs
like the liver, pancreas, and the pituitary gland.7,8 Since it is important for synthesis and
activation of enzymes (e.g., hyrdrolases, isomerases, ligases, lyases, oxidoreductases, and
transferases), it plays a role in protection of oxidative stress and also helps in the formation of
connective tissue and bone.7 The normal range of Mn ranges between 4-15 µg/L in blood. With
excess exposure it has been known to cause manganism that is manifested in neurological
symptoms that are similar to Parkinson’s disease.9 In the general population, the primary
pathway of exposure is through the consumption of food and water,9 but populations can have
environmental exposure if they reside closer to industries with Mn emissions.9 Workers from the
mining and welding industries have a greater risk from over exposure to Mn.10,11
A genetic animal study12 found that a certain amount of Mn exposure could reduce the
inflammatory response to stressful environments in rats. Mn protects cells from antioxidant
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processes as a cofactor for the metalloenzyme superoxide dismutase.13 An animal study14 by
Malecki et al. (1996) demonstrated that Mn deficiency leads to reduced Mn superoxide
dismutase (MnSOD) activity that caused in vivo oxidative stress to heart mitochondria in rats.
Thus, a subclinical Mn deficiency could increase oxidative stress. However, there is limited and
inconsistent information of the role of Mn from molecular biology and population-based studies.
Since, Mn deficiency and excess levels are both associated with adverse neurologic and
metabolic outcomes.15,16
Previous studies have investigated the association of Mn and myocardial infarction
(MI),17-21 stroke,19,22 and renal dysfunction.19 However, some of those studies used serum
Mn18,20,21 levels and one study used plasma Mn22 levels as the exposure. A case-control study17
found blood Mn levels were lower among those with MI and a study20 by Manthey et al. (1981)
found that plasma Mn levels were higher among those diagnosed with an MI. Two studies
investigated the association of Mn with stroke—one population based cross-sectional study used
blood Mn19 and the other case-control study22 used plasma Mn as the biomarker for exposure.
However, the studies that found an association or no positive association for these chronic
diseases had problems with adequate sample sizes17,18,20 or differing exposure biomarker.20,22
Oxidative stress and inflammation are the main pathophysiological processes underlying chronic
diseases.
Prior studies have not provided sufficient evidence to support associations of blood Mn
levels and the three chronic diseases. Therefore, we hypothesize that blood Mn levels could be
related to the prevalence of chronic diseases. The purpose of this cross-sectional study is to
describe the association of blood Mn levels with three chronic diseases (MI, stroke, and renal
dysfunction).
5

METHODS
Data source
The United States National Health and Nutrition Examination Survey (NHANES) is a complex,
stratified, multistage, probability cluster sampling design to select a representative sample of the
US civilian non-institutionalized population. Our analyses were limited to survey data cycles
from 2011-2012, 2013-2014, and 2015-2016 for participants 20 years and older (n=16245). The
overall response rate for the survey cycles for 2011-2012, 2013-2014, and 2015-2016 were
69.5%, 68.5%, and 58.7%, respectively. The NHANES is a unique survey which collects
participant information from questionnaires administered at home and standardized health
examinations conducted at specialized mobile examination centers (MECs).
The NHANES used a four-stage sample design for 2011-2016. The first stage is sampled
from a frame of all US counties known as the primary sampling units (PSUs). The PSUs were
mostly counties but in a few instances, adjacent counties were combined to keep the PSUs above
a certain minimum size. The PSUs for NHANES are chosen based on the probabilities
proportional to a measure of size (PPS) which corresponds to the population count of the PSU.
The second stage consists of the selection of area segments that comprise of census
blocks or a combination of blocks. The third stage consisted of the selection of dwelling units
(DUs). From the selected PSU, following the selection of the segments, a list of all DUs from the
sampled segments is prepared. A subsample of these DUs is carried out to in order to produce a
national probability of sampled households.
The fourth stage consists of the sampling of the persons from the occupied DUs or
households. From the list of all the eligible members of the household, a subsample of
6

individuals are selected based on age, sex, race, and Hispanic origin.23 Informed consent was
obtained from all participants for the personal interview and medical examination participants.
We further excluded women who were pregnant at the time of the survey because of the effect of
pregnancy on blood Mn levels.
Study variables
In NHANES, a standardized questionnaire is used to collect demographic information and
medical history. We defined cardiovascular disease as a self-reported history of MI and stroke.
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation,24 and renal dysfunction was defined as
albumin-to-creatinine ratio ≥30 mg/g or eGFR ≤60 ml/min/1.73 m2 using serum creatinine
levels. The other demographic covariates that are used were age group (20-44, 45-54, 55-64,
≥65), sex, race, and, poverty income ratio [(PIR), the ratio of self-reported family income to the
family’s appropriate threshold value based on federal poverty level, grouped in quartiles].
Mn levels were measured with whole blood specimens that were frozen (–30oC), stored, and
shipped for analysis to the Division of Laboratory Sciences, National Center for Environmental
Health (CDC). Whole blood Mn levels were measured in participants 20 years and older, using
inductively coupled plasma mass spectrometry (ICP-MS).
Statistical analysis
Descriptive results are presented based on MI, stroke, and renal dysfunction. Weighted mean and
standard errors were calculated for continuous variables (age and PIR), while weighted
frequencies with standard errors are reported for categorical variables. We used weighted
multivariable logistic regression to examine the association of blood Mn levels and MI, stroke,
7

and renal dysfunction adjusting for demographic variables like age, race, sex, and PIR and
reported odds ratios (ORs) and 95% confidence intervals (CIs). We further investigated
differences in blood Mn levels by PIR. The analyses for the combined years were re-weighted to
adjust for the complex sample survey design using SURVEYFREQ, SURVEYMEANS, and
SURVEYLOGISTIC procedures. All comparisons were considered statistically significant with
a p < 0.05. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) using
survey procedures.

RESULTS
This study included 16,229 adults aged 20 years and older from 2011-2016 NHANES surveys,
we excluded women who identified as pregnant (n=136) at the time of the survey. The
combined weighted prevalence of MI, stroke, and renal dysfunction was 3.3%, 2.9%, and 9.6%,
respectively (data not shown). Demographic characteristics, general health conditions, healthrelated behaviors, and blood Mn concentration (µg/L) by MI, stroke, and renal dysfunction are
presented in Table 1. The mean (SE) for blood Mn levels for MI was 10.2 µg/L, stroke (9.8
µg/L), and renal dysfunction (9.4 µg/L). The estimated blood Mn levels were lowest among
those with renal dysfunction compared to those without renal dysfunction (9.7 µg/L). The
distribution of blood Mn concentrations was 7.36, 9.07, and 11.29 for the 25th, 50th, and 75th
percentiles, respectively (data not shown). In comparison to age, the prevalence of self-reported
MI (10.3%) was highest among adults 65 years and olde, self-reported stroke (8.6%), renal
dysfunction (33.8%) compared to adults younger than 65 years. Prevalence of self-reported MI
(3.8%) and renal dysfunction (11.5%) was highest among Whites compared to persons Blacks,
Hispanic, and other races; while, Blacks had the highest prevalence of stroke (3.7%) compared to
8

Whites, Hispanic, and other races . Based on poverty income ratio (PIR), participants in the low
income level (1.3 to 3.49) had the highest prevalence of self-reported MI (4.5%), stroke (4.3%)
compared to middle- and high-income level groups; while, renal dysfunction (10.8%) was the
highest among middle income level compared to the low- and high-income levels . When
compared to smoking status, the prevalence of self-reported MI was highest among former
smokers (5.4%) compared to current smokers (4.5%) and never smokers (2.0%), while the
prevalence of self-reported stroke was highest among former smokers (4.3%), and the prevalence
of renal dysfunction was highest among former smokers (15.1%) followed by never smokers
(8.7%), and current smokers (5.0%).
We performed unadjusted and adjusted weighted multivariable logistic regression models
to determine the association between blood Mn, MI, stroke, and renal dysfunction with quartile 1
(≤7.36 µg/L) as the reference category (Table 2). In the unadjusted models, the odds of renal
dysfunction reduced for blood Mn quartiles Q2 to Q4 with a 36% reduction for Q4 (OR: 0.64,
95% CI: 0.52-0.77) compared to participants in blood Mn Q1 quartile. There were no significant
associations in the unadjusted models for MI Q2 (OR: 0.74, 95% CI: 0.53-1.03) and stroke Q3
(OR: 0.88, 95% CI: 0.54-1.44) compared to participants in blood Mn Q1. In the adjusted models
controlling for age group, sex, race, and PIR there was no significant association between blood
Mn Q4 (OR: 0.80, 95% CI: 0.62-1.05) and renal dysfunction compared to participants in Q1
blood Mn quartile. There were also no significant association for blood Mn Q2 (OR: 1.09, 95%
CI: 0.66-1.79) for stroke and Q2 (OR: 0.88, 95% CI: 0.54-1.44) for MI compared to Q1 blood
Mn quartile. We further investigated for effect measure modification of blood Mn and PIR in all
the models; however, the interaction was not statistically significant.
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DISCUSSION
In a nationally representative study from the US this study showed that blood Mn levels were not
associated with self-reported MI, stroke, and renal dysfunction after adjusting for
sociodemographic covariates. Blood Mn were lower among males compared to females and
Black males had lower blood Mn levels compared to White, Hispanic, and other races. We did
not find a positive association for blood Mn levels and MI, stroke, and renal dysfunction. This
suggests that blood Mn might not be involved in the pathophysiological processes for MI, stroke,
and renal dysfunction.
Blood Mn has been used as a biomarker in epidemiological studies, it has been used as an
exposure biomarker for Mn inhalation.13 Mn is found richly in tissues rich with mitochondria, at
present there is no reliable biomarker than can measure Mn accumulation accurately, due to a
discrepancy in the half-life of Mn in the tissues and blood.19 However, Mn levels in whole blood
are considered more reliable than plasma.13 Blood Mn levels were lower in participants with
renal dysfunction but not in participants with MI and stroke. Previous studies have explored the
relationship of Mn and MI,17-21 stroke,19,22 and renal dysfunction, two of those studies for MI
used blood Mn levels as the biomarker, while the other three studies used plasma Mn levels. Of
the studies with blood Mn as the biomarker, one case-control study17 found that lower blood Mn
levels were associated with MI; however, the findings are questionable given the lack of
adequate controls in the study. The other population-based cross-sectional study19 from Korea
found that there was no association between blood Mn and MI; although, they had a 45.0% nonsignificant lower odds in the highest blood Mn quartile (15.6 µg/L) compared to Q1 (≤10.5
µg/L). There were two studies for stroke and one cross-sectional study19 used blood Mn as a
biomarker that did not find an association with blood Mn levels; however, we found a similar
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non-significant 20% increase of the odds of stroke in the highest quartile (11.3 µg/L). The other
case-control study22 from China used plasma Mn levels and found that the highest quartile
(>41.8 µg/L) had a 3-fold increased odds of stroke compared to the first quartile (<17.7 µg/L) of
plasma Mn levels. There was one cross-sectional study19 by Koh et al. (2014) on blood Mn levels
and renal dysfunction that found blood Mn levels between (10.6 to 12.7 µg/L) had a 49% lower
odds of renal dysfunction, while we found a 20% non-significant lower odds in blood Mn levels
(>11.3 µg/L) . Although we did not find an association in the adjusted model for renal
dysfunction, our adjusted model controlled for sociodemographic and socioeconomic factors,
while the Koh et al. (2014) study19 adjusted for body mass index (BMI), diabetes, and
hypertension in addition to age and sex.
This is the first population-based study in the US using a nationally representative
general US population that examined the association of blood Mn and MI, stroke, and renal
dysfunction. Most studies have found environmental Mn toxicity to be associated with adverse
outcomes compared to dietary intake and metabolism.15,25 Mn toxicity occurs due to chronic
inhalation with high concentration of Mn particles in the air.25,26 This toxicity has been mainly
observed in miners, ferroalloy workers, and battery manufacturing workers.15,26 Since, oxidative
stress plays an important role in atherosclerosis and manganese superoxide dismutase (MnSOD)
is transcriptionally transported to the mitochondria, several studies27,28 have shown that MnSOD
polymorphisms induce oxidative stress and could lead to severe cardiac outcomes. In the US, Mn
exposure can occur among miners, ferroalloy workers, and residents that live in close proximity
to the mining industries. Mn toxicity has been known to induce tremors, rigidity, postural
instability that closely resemble idiopathic Parkinson’s disease.29 some patients exhibit
neuropsychological symptoms like apathy and psychosis as it targets the dopaminergic system of
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the brain that mimics Parkinson’s disease.29 Although, we did not find an association with renal
dysfunction, one study19 in Korea did find a statistically significant association with lower blood
Mn levels. Nevertheless, this association needs to be examined further to verify this hypothesis.
This study had some important limitations. First, we used a cross-sectional study design,
and therefore, we cannot make any temporal associations with the simultaneous assessment of or
outcomes and exposure. Therefore, we could not assess the changes in blood Mn levels over time
to establish a causal association. Some of the outcomes were based on self-reports by the
participants, thus we could underestimate or overestimate our findings. Some of our adjusted
models could be affected by unmeasured variables such as serum iron or albumin levels that are
important proteins in Mn-binding in the blood. Although, we looked for correlations with other
heavy metals in blood like lead, selenium, cadmium, and mercury, we were unable to adjust for
metals that have the same valence states as Mn like copper and calcium. There is a possibility
that some of the participants with chronic diseases may not have had Mn readings that could
affect the lack of association in our study. Lastly, we were not able to classify participants based
on their occupation due to a large percentage of missing observations. Despite these limitations,
we used a nationally representative US general population using standard analytical and quality
control procedures of NHANES.
In conclusion, we found blood Mn is not associated with MI, stroke, and renal
dysfunction. However, further prospective cohort studies are needed to determine protective or
adverse effects of Mn for renal dysfunction.
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TABLES

Table 1. Participant characteristics of blood manganese (Mn) (µg/L) according to self-reported
myocardial infarction, stroke, and renal dysfunction status among US adults aged 20 years and
older—NHANES, 2011-2016
Myocardial infarction
Stroke
Renal dysfunction
Yes
No
Yes
No
Yes
No
Characteristics
Age group, y
20-44
45-54
55-64
≥65
Sex, (male)
Race
White
Black
Hispanic
Other
PIR
<1.3
1.3-3.49
≥3.5
BMI, Kg/m2
Normal
Overweight
Obsese
Cigarette
smoker
Current
Former
Never
Diabetes
Hypertension
Blood Mn
(µg/L), mean
(SE)

n

%

n

%

n

%

n

%

n

%

n

%

40
53
155
407
412

0.5
1.4
5.1
10.3
4.1

6886
2723
2649
3316
7492

99.5
98.6
94.8
89.7
95.9

45
64
143
356
294

0.6
1.7
3.6
8.6
2.7

6884
2711
2661
3368
7613

99.4
98.3
96.4
91.4
97.3

56
126
304
1310
871

0.8
5.0
10.5
33.8
8.3

6874
2651
2501
2423
7042

99.2
95.0
89.5
66.2
91.8

338
127
132
58

3.8
2.7
1.9
3.0

5746
3552
3809
2467

96.2
97.3
98.0
97.0

274
171
108
55

2.9
3.7
1.8
3.0

5813
3511
3829
2471

97.1
96.2
98.2
97.0

972
381
294
149

11.5
8.0
4.3
5.5

5120
3301
3650
2378

88.5
92.0
95.7
94.5

273
207
115

4.5
3.7
2.2

4805
5123
4275

95.5
96.3
97.8

240
226
90

4.3
3.5
1.5

4840
5104
4300

95.6
96.5
98.5

565
660
412

9.5
10.8
8.5

4519
4674
3980

90.5
89.2
91.5

137
196
287

2.3
3.0
4.1

4384
4941
5802

97.7
97.0
95.9

144
180
239

2.5
2.5
3.1

4379
4960
5847

97.5
97.5
96.9

361
611
759

7.4
10.2
10.5

4166
4530
5335

92.6
89.8
89.5

159
261
234
239
509

4.5
5.4
2.0
10.8
7.5

3062
3482
9013
1944
5461

95.4
94.6
97.9
89.2
92.6

150
213
245
202
458

3.6
4.3
2.0
8.4
6.5

3072
3530
9004
1984
5513

96.4
95.7
98.0
91.6
93.5

213
687
894
574
1314

5.0
15.1
8.7
24.7
19.9

3010
3063
8359
1613
4664

95.0
84.9
91.3
75.3
80.1

9.6

0.2

9.7

0.1

9.6

0.2

9.7

0.1

9.2

0.1

9.7

0.1

Abbreviations: Body mass index (BMI); normal = 18.5-24.9, overweight = 25.0-29.9, obese = 30.0 and above. PIR,
(poverty income ratio); low <1.3, middle = 1.3 to 3.49, high ≥3.5.
Note: Renal dysfunction was calculated using CKD-EPI equation eGFR = 141 x min(SCr/κ, 1)α x max(SCr /κ, 1)1.209 x 0.993age x 1.018 [if female] x 1.159 [if Black]. eGFR < 65 is defined renal dysfunction.
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Table 2. Estimates of unadjusted and adjusted logistic regression analysis of blood Mn (mcg/dL)
and myocardial infarction, stroke, and renal dysfunction among adults 20 years and older—
NHANES, 2011-2016.
Myocardial infarction
Stroke
Renal dysfunction
OR (95% CI)
OR (95% CI)
OR (95% CI)
Characteristics Unadjusted Adjusted Unadjusted
Adjusted
Unadjusted
Adjusted
Mn quartile
(µg/L)
Q1 (≤7.36)
Ref
Ref
Ref
Ref
Ref
Ref
Q2 (7.37-9.06)
0.74
0.88
0.98
1.10
0.77
0.87
(0.53-1.03) (0.60-1.27) (0.62-1.56) (0.72-1.72) (0.62-0.95)
(0.67-1.12)
Q3 (9.070.84
1.11
0.88
1.09
0.74
0.97
11.29)
(0.55-1.28) (0.68-1.81) (0.54-1.44) (0.66-1.79) (0.61-0.91)
(0.75-1.24)
Q4 (≥11.3)
0.94
1.20
0.91
1.17
0.64
0.80
(0.66-1.34) (0.76-1.90) (0.57-1.47) (0.72-1.92) (0.52-0.77)
(0.62-1.05)
Age group,
years
20-44
Ref
Ref
Ref
Ref
Ref
Ref
45-54
2.80
3.74
2.90
4.45
6.52
6.31
(1.85-4.22) (2.17-6.46) (1.86-4.53) (2.41-8.19) (4.46-9.52)
(3.98-9.99)
55-64
10.86
13.45
6.14
7.84
14.65
15.8
(7.32-16.12) (7.5-24.1) (3.97-9.50)
(4.2-14.7)
(9.7-22.2)
(8.9-28.0)
≥65
23.1
27.6
15.6
20.5
63.9
62.97
(16.29-32.7) (16.8-45.3) (10.9-22.5) (12.4-33.9) (45.7-90.3)
(41.0-96.6)
Sex
Female
Ref
Ref
Ref
Ref
Ref
Ref
Male
1.64
2.03
0.87
1.04
0.31
0.83
(1.34-2.01) (1.50-2.73) (0.70-1.10) (0.79-1.36) (0.02-4.25)
(0.67-1.04)
Race
White
Ref
Ref
Ref
Ref
Ref
Ref
Black
0.70
0.95
1.31
1.37
0.67
0.96
(0.56-0.88) (0.65-1.37) (1.08-1.57)
(1.08-1.75) (0.58-0.76)
(0.79-1.17)
Hispanic
0.51
0.71
0.62
0.8
0.35
0.61
(0.39-0.66) (0.54-0.92) (0.49-0.78) (0.56-1.14)
(0.29-0.42) (0.48-0.81)
Other
0.79
0.75
1.06
1.10 (0.620.45
0.62
(0.50-1.25) (0.45-1.27) (0.69-1.62)
1.97)
(0.35-0.57) (0.47-0.81)
PIR
<1.3
Ref
Ref
Ref
Ref
Ref
Ref
1.3-3.49
2.07
3.00
3.01
4.08
1.13
1.55
(1.50-2.86) (1.95-4.60) (2.16-4.19) (2.69-6.19) (0.92-1.39)
(1.26-1.90)
≥3.5
1.67
1.86
2.41
2.39
1.29
1.22
(1.14-2.45) (1.09-3.17) (1.80-3.23) (1.66-3.42) (1.14-1.48)
(0.98-1.53)
Abbreviations: Odds ratio (OR); confidence interval (CI). PIR [poverty income ratio; low (<1.3), middle
(1.3 to 3.49), high (≥3.5)].
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FIGURES
Figure 1. Estimated blood Mn levels (µg/L) according to sex and race/ethnicity among
adults 20 years and older—NHANES, 2011-2016

Figure 2. Estimated blood Mn levels (µg/L) by age-group (years) among adults aged 20
years and older—NHANES, 2011-2016
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ABSTRACT
Introduction: The objective of this study was to estimate the influence of the Affordable Care
Act (ACA) Medicaid Expansion on current smoking and quit attempts in expanded and nonexpanded states.
Methods: We analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS)
between 2003 through 2015 to evaluate changes in current smoking and quit attempts using
multivariable logistic regression and generalized estimating equations (GEE), adjusting for
socioeconomic factors. Time periods evaluated were: 2003-2009 (pre-expansion) and 2011-2015
(post-expansion), and in supplemental analysis, also 2011- 2017.
Results: Overall, smoking prevalence among adults in expanded and non-expanded states were
16% and 17% (p < 0.001), respectively, and quit attempt prevalence for expanded and nonexpanded states were 56% and 57% (p = 0.05), respectively. In adjusted models comparing postversus pre- expansion periods, current smoking declined by 6% in both expanded (RR: 0.94,
95% CI: 0.93-0.94) and non-expanded (RR: 0.94, 95% CI: 0.94-0.95) states. Quit attempts
increased by 4% (RR: 1.04, 95% CI: 1.04-1.05) in expanded states, and by 3% (RR: 1.03, 95%
CI: 1.02-1.03) in non-expanded states. States that imposed barriers to utilization of smoking
cessation services e.g. prior authorization, saw only a 3% increase in quit attempts regardless of
expansion status, while expanded states that did not impose barriers experienced a 6% (RR: 1.06,
95% CI: 1.05-1.06) increase in quit attempts.
Conclusion: Reducing administrative barriers to smoking cessation programs may enhance
further declines in smoking rates among US adults.
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CHAPTER 3
INTRODUCTION
Cigarette smoking is the leading cause of preventable morbidity and mortality in the United
States and accounts for approximately 480,000 deaths each year.1,2 There have been significant
declines in cigarette smoking, from 42% in 1965 to 15% in 2015.3 However, current smoking
remains disproportionately higher among low-income (30%) and uninsured (28%) individuals.4
The Affordable Care Act (ACA), introduced in 2010, addressed provisions for healthcare
coverage denial due to pre-existing conditions, provided tax-credits and subsidies to purchase
health insurance and access to free preventive care, and expanded insurance coverage to include
non-disabled single childless adults.5-7 As part of the ACA provision, childless adults could be
Medicaid eligible at or below 133 percent federal poverty level (FPL).7 A total of 30 US states
including the District of Columbia had expanded Medicaid as part of the ACA by December 31,
2015, however in March 2010, six states and jurisdictions—California, Connecticut, the District
of Columbia, Minnesota, New Jersey, and Washington— enacted Medicaid expansion among
low-income groups due to the provisions in the ACA.8
Prior to the ACA, low-income adults without Medicaid coverage had few available
choices for accessing smoking cessation services and states had flexibility in types of smoking
cessation services offered through Medicaid.9 However, following the implementation of the
ACA, state Medicaid programs were required to cover smoking cessation services among newly
eligible adults,10 leading to expanded coverage of evidence-based smoking cessation treatments.
Previous studies have evaluated the impact of ACA expansion on quit attempts and current
smoking, however prior studies have only evaluated annual trends, focused on a single or few
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US states, or did not account for baseline differences in states Medicaid expansion status.11-14
The purpose of this study is to evaluate the impact of the ACA expansion on current smoking
and quit attempts among expanded and non-expanded US states, to evaluate the impact among
low-income individuals, and to account for state-level barriers to smoking cessation services.

METHODS
Data source: Data were obtained from the Behavioral Risk Factor Surveillance System (BRFSS)
for adults 18 years and older surveyed between 2003 and 2017.15 The BRFSS collects nationally
representative data annually on randomly selected land-line and cell-phone telephone numbers
on over 400,000 adults in all 50 states, including three U.S. territories and the District of
Columbia.16 The annual telephone survey obtains information on health related risk behaviors,
chronic health conditions and use of preventive services. The BRFSS median response rate over
the study period ranged from 53% in 2003 to 47% in 2015.15 In the current analyses, data on
socio-demographics, current smoking and quit attempts were obtained from the BRFSS, and data
on Medicaid expansion status and year of expansion by state was obtained from the Kaiser
Family Foundation State Health Facts.17
Study variables: Outcome variables of interest were current smoking and quit-attempts in the
past year among smokers. Current smokers were defined as participants who indicated that they
currently smoked every day or some days, or that they had smoked a cigarette within the past
month. Quit-attempts among smokers was defined as having a quit-attempt in the preceding 12
months for one day or longer. Current smoking was defined using the ‘computed smoking status’
variable, while quit-attempts was defined using the variable ‘_STOPSMK2’ in the past year
among current smokers. Sociodemographic characteristics, including age, sex, race/ethnicity,
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education, employment status, and annual household income were obtained, and data on
availability of regular healthcare providers and health care coverage were included to examine
access to healthcare. Age variable was classified in three groups; 18 – 49, 50 – 79, and 80+ years
of age; annual household income variable was categorized into four groups- <$10,000, $10,000<$20,000, $20,000-<$50,000, and ≥$50,000; race was identified using the five level
race/ethnicity variable and classified into White, Black, Hispanic, and Other categories;
education was categorized into <high school, high school graduate, and some college or higher.
Healthcare coverage was ascertained as having any kind of coverage, including health insurance,
prepaid plans such as Health Maintenance Organizations (HMOs), or government plans like
Medicare, or Indian Health Service. To evaluate the impact of state-level barriers to utilization of
smoking cessation services, data on two state-level barrier variables – prior authorization before
smoking cessation treatment and copayments- were obtained from the American Lung
Association for 2010, dichotomized as yes/no.18
Study Periods: The two study periods, pre-expansion (2003–2009) and post-expansion (2011–
2015), were defined based on states’ Medicaid expansion status during the study period. Five
states and the District of Columbia expanded eligibility as early as 2010 by taking advantage of
provisions in the ACA and Medicaid waivers,7,8 therefore we considered the year 2010 as the
washout period. By 2015, the following states had expanded Medicaid as part of the ACA;
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Indiana, Iowa,
Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire,
New Jersey, New Mexico, New York, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island,
Vermont, Washington, West Virginia, and District of Columbia. To evaluate more recent trends
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in current smoking and smoking cessation, we also examined BRFSS data from 2011 to 2017;
comparing 2011-2013 and 2015-2017 time periods.
Statistical analysis: Weighted analyses for descriptive variables by expansion status using chisquare tests, were evaluated for current smoking and quit attempts by socio-demographic
variables and expansion status. We assessed annual trends in current smoking and quit attempts
by expansion status, and utilized multivariable adjusted logistic regression and generalized
estimating equations (GEE) to assess current smoking and quit attempts in the past year in nonexpanded versus expanded states for each time period. Due to the high prevalence of current
smoking and quit attempts in the past year, we interpret estimates from GEE models as relative
risks (RRs) instead of odds ratios (ORs).19 To examine the secular time trends in the prevalence
of current smoking and quit-attempt status among adults in the two time periods, we assessed for
linear and quadratic changes adjusting for socio-demographic and socio-economic predictors in
pre-expansion (2003–2009) and post-expansion (2011–2015) periods. Similar analyses were
conducted for 2011-2013 versus 2015-2017 (supplemental tables). We also assessed for
interactions between expansion status and time periods in prevalence of current smoking and
quit-attempts. Furthermore, we evaluated whether the association between expansion and
smoking cessation varied by state-level barriers such as prior authorization and co-payments for
smoking cessation treatment. All analyses were carried out using SAS version 9.4 (SAS Institute,
Inc., Cary, NC; USA) accounting for the complex sample survey design; statistical significance
levels were determined based on p-values < 0.05.
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RESULTS
By December 31, 2015, 30 states and DC had implemented Medicaid expansion, while 21 states
had not implemented the policy. A total of 5,311,872 participants were included in this analysis,
2,289,033 (43%) were in non-expanded states and 3,022,839 (57%) were in expanded states
(Table 1). Table 1 shows the baseline characteristics of the study participants overall and by
Medicaid expansion status. Participants in expanded vs. non-expanded states were less likely to
be Black (7% vs. 10%), more likely to be Hispanic (7% vs. 5%), have at least some college
education (64% vs. 60%), have an average annual household income of >$50,000 (47% vs.
41%), more likely to have health insurance coverage (91% vs. 88%) and at least one regular
healthcare provider (86% vs. 84%).
Overall, 16% of participants residing in expanded states were current smokers, compared
with 17% of participants in non-expanded states (Table 2; p<0.001). The prevalence of current
smoking in the expanded states declined from 23% to 14%, and in the non-expanded states
reduced from 22% to 15% between 2003 and 2015 (Figure 1). For quit attempts, prevalence in
expanded states increased from 53% to 57%, and in the non-expanded states it increased from
51% to 58% (Figure 2). Current smoking was lower in expanded vs. non-expanded states,
especially among participants aged 18-34 (22% vs. 23%), those without health insurance
coverage (31% vs. 33%), those with an annual household income less than $10,000 (31% vs.
32%) and those who were unemployed (30% vs. 34%). The prevalence of current smoking in the
expanded states declined from 23% to 14%, and in the non-expanded states reduced from 22% to
15% between 2003 and 2015 (Figure 1). For quit attempts, prevalence in expanded states
increased from 53% to 57%, and in the non-expanded states it increased from 51% to 58%
(Figure 2).
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In models adjusted for sex, race, income, education, and comparing non-expanded versus
expanded states (Table 3), current smoking increased by 2% (RR: 1.02, 95% CI: 1.02-1.03) in
the pre-expansion period (2003-2009), but no significant difference was found post-expansion
(RR: 0.99, 95% CI: 0.99-1.00) . In addition, quit attempts declined by 2% pre-expansion (RR:
0.98, 95% CI: 0.98-0.99), and increased by 1% (RR: 1.01, 95% CI: 1.01-1.02) post-expansion. In
Table 4, comparing post- versus pre- expansion periods, current smoking declined by 6% in both
expanded (RR: 0.94, 95% CI: 0.93-0.94) and non-expanded (RR: 0.94, 95% CI: 0.94-0.95)
states. Quit attempts increased by 4% (RR: 1.04, 95% CI: 1.04-1.05) in expanded states postversus pre- expansion, and by 3% (RR: 1.03, 95% CI: 1.02-1.03) in non-expanded states. When
focused on low income individuals (annual household income <$20,000), there was no
significant change in current smoking post versus pre- expansion in either expanded or nonexpanded sates, but there quit attempts increased by 5% (RR: 1.05, 95% CI: 1.05-1.06) in
expanded states and by 4% (RR: 1.04, 95% CI: 1.04-1.05) in non-expanded states. More modest
associations were observed in more recent BRFSS years (2011-2017); current smoking declined
by 1% (RR: 0.99, 95% CI: 0.99-0.99) in 2011-2013, and increased by 1% (RR: 1.01, 95% CI:
1.01-1.01) in 2015-2017. Quit attempts increased by 0.6% (RR: 1.006, 95% CI: 1.006-1.007) in
2011-2013 period, and by 1% (RR: 1.01, 95% CI: 1.01-1.01) in 2015-2017. (Supplemental
Tables 1-2).
We further examined the association between Medicaid expansion and current smoking
or quit attempts varied by state-level prior authorization and co-payment barriers. Among states
that required prior authorization (Table 5), quit attempts increased by 3% (RR: 1.03, 95% CI:
1.02-1.03) in the post versus pre-expansion period in both expanded and non-expanded states.
However, among states that did not require prior authorization for smoking cessation, quit
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attempts increased by 6% (RR: 1.06, 95% CI: 1.05-1.06) in expanded states, and increased by
3% (RR: 1.03, 95% CI: 1.02-1.03) in non-expanded states. Among states that required copayments for smoking cessation services (Table 6), quit attempts increased by 3% (RR: 1.03,
95% CI: 1.02-1.03) in expanded states, and by 2% (RR: 1.02, 95% CI: 1.02-1.03) in nonexpanded states. Among states that did not require copayments, quit attempts increased by 7%
(RR: 1.07, 95% CI: 1.06-1.07) in expanded states, and by 3% in non-expanded states (RR: 1.03,
95% CI: 1.03-1.04).

DISCUSSION
In a large nationally representative study population of US adults, we examined the impact of the
ACA expansion on current smoking and quit attempts in pre-expansion and post-expansion time
periods. Overall, current smoking was 2% higher in the non-expanded versus expanded states in
the pre-expansion period, but 1% lower post-expansion. However, in both expanded and nonexpanded states, there was a 6% decline in current smoking post- versus pre-expansion, and a 34% increase in quit attempts. There was no significant change in current smoking among
participants with an annual household income of ≤$20,000, but a 4-5% increase in quit attempts
was observed in this group. These results indicate that while non-expanded states had higher
current smoking rates compared with expanded states pre-expansion, following implementation
of the ACA Medicaid expansion policy, both expanded and non-expanded states experienced
significant improvements in declining current smoking rates and higher quit attempts. However,
expanded states that introduced barriers to accessing evidence based smoking cessation services,
specifically prior authorization and co-payments, experienced very modest increases in quit
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attempts post- versus pre- expansion, compared with states that did not institute such barriers,
while such barriers made no difference in non-expanded states.
Prior studies have analyzed the impact of Medicaid expansion on current smoking and
quit attempt rates among US adults.2,20-24 The majority of those studies observed that following
the implementation of Medicaid expansion as part of the Affordable Care Act, current smoking
rates declined modestly,2,20,22,23 while quit attempts increased.2,21,24 Three studies utilized data
from BRFSS to evaluate differences in current smoking post- versus pre-expansion and observed
declines in current smoking ranging from 15%20 and 7%22 to 0.06%.23 Other studies have
evaluated differences in prevalence of current smoking comparing trends over time,2,20,21,23 a
study using the National Health Interview Survey (NHIS) observed that current smoking
prevalence was 21% in 2005 and 15% in 2015,4 while a state-based study using the
Massachusetts BRFSS observed that smoking prevalence decreased from 38% in 1999 to 28% in
2008.20 Two studies using the BRFSS evaluated the effect of Medicaid expansion on quit
attempts in the pre- versus post-expansion period, and observed that the odds of smoking
cessation increased by 21% among US adults,22 while the other study observed that nonexpanded Medicaid enrollees had a 5% lower odds of quit attempts compared with enrollees.24
Other studies have utilized data from specific states to evaluate expansion and quit attempts. For
instance, a study of Medicaid enrollees in Alabama, Georgia, and Maine observed that the odds
of quit attempts increased by 60% after the Medicaid expansion,25 while a study from northern
California showed a 49% increase among Medicaid enrollees compared to those on commercial
insurance.24 There are several potential reasons for the differences between these prior studies
and our findings.
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Compared with other studies,2,20,22,23 we observed a more modest 6% decline in current
smoking among US adults in both expanded and non-expanded states comparing post- and preexpansion periods. That is, regardless of whether a state expanded Medicaid as part of the
Affordable Care Act, current smoking declined by 6%, while quit attempts increased by 3-4%.
Among low-income individuals, we did not observe a significant decline in current smoking, but
did observe a 4-5% increase in quit attempts. This is similar to a 2% increase in quit attempts
observed by a separate study12 using the BRFSS dataset. Our findings of current smoking
prevalence of 26% in the non-expanded and 18% in the expanded states for participants of Other
races (includes multiracial, American Indian/Alaska Native, and Asians) are also comparatively
lower compared to a previous study4 using the NHIS that had a prevalence of 32% among
American Indian/Alaska Natives. The lower rates could be due to the combination of racial
groups i.e. American Indian/Alaska Natives and Asians with significantly different current
smoking rates. Moreover, our results are based on an overall population average for 2003 to
2015, while the NHIS study reported cross-sectional results for 2015.4
The modest findings in our study may be explained by several possible reasons. First, in
contrast to other studies, our analytic approach did not assume that states that expanded
Medicaid as part of the Affordable Care Act were similar to states that did not expand at
baseline. For instance, individuals in expanded states were younger, less likely to be Black, and
had higher annual household incomes on average compared with individuals in states that did not
expand. To account for these baseline differences, we estimated the risks of current smoking and
smoking cessation in pre- versus post-expansion separately in expanded and non-expanded
states, and statistically adjusted for these demographic differences.
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Second, the modest declines in current smoking observed may be due to administrative and/or
logistical barriers in accessing smoking cessation services that remained unaddressed or were
newly implemented in some states after Medicaid expansion, a factor that was not directly
considered in other studies. For instance, of the 31 states and jurisdictions that expanded
Medicaid, only 19 states covered all the FDA-approved medications, while only 17 covered
individual and 11 covered group counselling.26 Furthermore, some of the expanded states
established administrative barriers such as co-payments and prior authorization for available
treatments, therefore limiting access for cessation programs.27 In addition, prior to 2015, 48
states covered some cessation treatments, but by June 2017, all of the 50 states and DC covered
some form of tobacco cessation treatments.27 These may explain our observation of similar
declines in current smoking and quit attempt rates between expanded and non-expanded states.
That is, the added benefit of Medicaid expansion in improving access to smoking cessation
services and hence reducing smoking rates may have been muted by accessibility barriers in
expanded states, and provision of at least some smoking cessation services in non-expanded
states. Based on our analyses, expanded states that had no barriers to smoking cessation
treatments had a 7% increase in quit-attempts compared to a 3% increase among expanded states
that had barriers in the post-expansion period. However, it is important to evaluate changes over
time as benefits included in Medicaid coverage can change over time, for example North Dakota
and Pennsylvania initially covered all cessation treatments, but no longer did so by June 2017.27
Third, provision of smoking cessation services without other health policies such as
indoor smoking bans, cigarette excise taxes and stricter age-limits, are likely to have limited the
effectiveness of Medicaid expansion on smoking cessation. As of Jan 2018, only 28 states and
D.C. have instituted a statewide smoking ban policy, and 47 states have increased cigarette taxes
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with an average state tax of $1.69 per pack, ranging from $0.33 to $5.1.28 A 15% decline in
current smoking was reported in Massachusetts,20 the first state to establish a Medicaid
expansion program for low-income individuals. The program also provided fewer restrictions to
participants, including lower administrative barriers to cessation services, and simultaneously
implemented other smoking cessation policies such as indoor bans and higher excise taxes that
likely contributed to its success.20 Treatment effectiveness may also vary- one study29 compared
success rates in quitting gradually vs. abruptly found a significant quit rate (15% vs. 22%) at the
end of six months in primary care clinics in England when included with behavioral support and
nicotine replacement. A prior study has also reported that almost 85% of smokers quit smoking
abruptly.30 We were unable to ascertain if our rates of quit attempts were based on counseling
and nicotine replacement or just quit ‘cold-turkey’ as the BRFSS participants were not asked
regarding cessation treatments.
Fourth, Medicaid expansion was designed to increase insurance coverage for low-income
individuals. Our study found no significant difference in current smoking in both the expanded
and non-expanded states among low-income adults. This may be partly due to the increase in the
Medicaid population over time; in 1997 low-income adults represented 8% of the US adult
population, but by 2013 it had doubled almost to almost 17.31 In addition, many low-income
individuals initiate smoking due to intense exposure to advertising, and personal psychosocial
factors such as stress, financial burdens, and lack of social support.32-34 Medicaid expansion by
itself is unlikely to address all these issues, and states may need to enhance tobacco cessation
programs with other strategies including advertising restrictions especially for younger
individuals, free or low-cost counseling and policies to further limit exposure to cigarettes.
Current smoking was higher among 18-49-year olds in our study in non-expanded (21%) and
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expanded (20%) states compared with other age-groups evaluated, highlighting the need for
greater access to comprehensive smoking cessation services with limited financial and logistical
barriers to utilization among younger adults.
The strengths of our study are the use of a nationally representative non-institutionalized
population of US adults across a wide range of racial, and socio-economic age groups. Our study
estimates are reliable due to the large sample size across all sub-populations that provided
adequate statistical power for the analysis. Also, we were able to assess study outcomes
specifically among low-income individuals, since Medicaid expansion was designed to improve
insurance coverage in this sub-population. There are also certain limitations relevant to our
study. First, we relied on self-reported data on smoking status and quit attempts, however, selfreports of these variables have been validated previously.35 Second, measuring the impact of a
general policy on individuals is vulnerable to ecological bias. Studies of low-income individuals
comparing those enrolled in Medicaid as part of the Affordable Care Act with those who
remained uninsured can provide better estimates of the direct association between expansion and
smoking outcomes. We did not account for the time-varying nature of state-level barriers across
the study period, but obtained data on barriers for the calendar year 2010. Lastly, the weighting
methodology for BRFSS changed in 2010, thus estimates after 2011 were not comparable to
previous years.36 To account for this, we examined the trends in the pre-expansion period (20032009) and post-expansion periods (2011-2015) by categorizing expanded and non-expanded
states, and examined the trends while considering calendar year 2010 as our wash-out period.
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CONCLUSION
In summary, our findings provide evidence that current smoking rates declined and quit attempts
increased post-Medicaid expansion period; however, these trends were observed in both
expanded and non-expanded states and were significantly influenced by state-level barriers to
access smoking cessation services. Eliminating financial and logistical barriers to cessation
services among Medicaid enrollees, and implementation of smoking related policies such as the
indoor smoking ban and excise taxes may help to further reduce current smoking rates among
US adults.
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APPENDIX
Table 1: Baseline characteristics of study population by Medicaid expansion status, BRFSS 2003-2015 (unweighted).
Expansion
Non-expanded
Expanded
Total
Characteristics
States (21)
States (30)
p value
(N = 5,311,872)
(N = 2,289,033)
(N = 3,022,839)
Age
18-34
796,657 (14.49)
345,041 (14.57)
451,616 (14.42)
<.0001
35-49
1,219,456 (21.20)
509,427 (20.57)
710,029 (21.70)
50-64
1,642,264 (31.84)
701,298 (31.41)
940,966 (32.17)
65-79
1,199,499 (24.25)
536,075 (25.0)
663,424 (23.68)
≥ 80
403,594 (8.19)
178,504 (8.43)
225,090 (8.02)
Sex
Male
2,086,990 (39.98)
888,554 (39.46)
1,198,436 (40.36)
<.0001
Female
3,224,809 (60.02)
1,400,434 (60.54)
1,824,375 (59.64)
Race
White
4,176,702 (79.36)
1,814,675 (80.08)
2,362,027 (78.81)
<0.001
Black
429,021 (8.18)
225,859 (9.92)
203,162 (6.84)
Other race
301,577 (5.87)
102,984 (4.56)
198,593 (6.88)
Hispanic
336,421 (6.57)
118,687 (5.42)
217,734 (7.45)
Education
< High school
492,197 (8.78)
237,869 (9.80)
254328 (7.99)
<0.001
High school grad
1,576,718 (29.34)
492,197 (30.66)
710105 (28.33)
Some college or higher
3,222,435 (61.87)
1,333,728 (59.53)
1888707 (63.66)
Income level
< $10,000
247,936 (5.38)
114,579 (5.73)
133,357 (5.11)
<0.001
$10,000 – < $20,000
637,669 (13.89)
299,939 (15.15)
337,730 (12.93)
$20,000 – < $50,000
1,717,152 (36.54)
778,781 (38.59)
938,371 (34.97)
≥ 50,000
1,947,866 (44.17)
762,843 (40.51)
1,185,023 (46.98)
Employment
Employed
2,296,526 (42.05)
962,264 (40.73)
1,334,262 (43.07)
<0.001
Self-employed
452,022 (8.39)
199,625 (8.63)
252,397 (8.21)
Unemployed
257,218 (5.03)
102,243 (4.64)
154,975 (5.32)
Student/Homemaker/Retired
1,073,783 (37.35)
843,350 (38.12)
1,073,783 (36.75)
Unable to work
189,519 (7.16)
170,996 (7.86)
189,519 (6.62)
Marital Status
Married
2,878,492 (53.94)
1,273,187 (55.28)
1,605,305 (52.91)
<0.001
Divorced/Widowed/Separated
1,557,951 (29.61)
687,999 (30.28)
869,952 (29.10)
Never married/Unmarried couple
847,402 (16.44)
317,997 (14.43)
529,405 (17.97)
Healthcare Coverage *
Yes
4,718,672 (89.74)
1,996,128 (88.09)
2,722,544 (91.00)
<0.001
No
576,588 (10.25)
285,477 (11.90)
291,111 (8.92)
Healthcare Providers +
At least one
4,523,661 (85.45)
1,925,100 (84.30)
2,598,561 (86.34)
<0.001
No
769,281 (14.54)
357,067 (15.70)
412,214 (13.65)
() Denotes column percentage. Sample sizes are unweighted; percentages are weighted to adjust for sampling and post-stratification.
*Healthcare coverage is defined as having any kind of health care coverage, including health insurance, prepaid plans such as HMOs, or
government plans such as Medicare.
+Healthcare providers is defined as personal doctor or health care provider.
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Table 2: Smoking Status by study period in the expanded and non-expanded states, BRFSS 2003 – 2015 (N
= 5,311,799).
Smoking Status
Current Smoker*
Non-expanded
Expanded
398,437 (16.6)
499,893 (15.90)

Quit Attempts
Characteristics
p value
Non-expanded
Expanded
p value
Overall
<.0001
219,367 (56.61)
275,150 (56.38)
0.05
Socio-Demographics
Age
18-34
79,937 (22.46)
100,966 (21.56)
<.0001
51,018 (65.40)
63,752 (64.19)
<.0001
35-49
113,117 (20.99)
145,667 (19.56)
62,426 (57.16)
81,325 (57.44)
50-64
138,497 (19.45)
172,103 (18.15)
74,064 (54.76)
92,100 (54.70)
65-79
58,565 (10.81)
69,600 (10.46)
29,223 (50.78)
34,515 (50.38)
≥ 80
6,264 (3.46)
8,242 (3.59)
2,636 (42.73)
3,458 (42.43)
Sex
Male
169,434 (18.32)
213,833 (17.27)
<.0001
89,239 (53.96)
114,084 (54.54)
<.0001
Female
229,003 (15.58)
286,060 (14.98)
131,173 (58.60)
162,750 (57.84)
Race
White
307,000 (16.07)
384,156 (15.52)
<.0001
161,934 (53.97)
204,189 (54.01)
<.0001
Black
42,342 (18.60)
39,288 (19.40)
28,883 (69.41)
26,314 (68.15)
Other race
27,570 (26.12)
37,223 (18.16)
16,461 (60.68)
21,917 (59.81)
Hispanic
17,545 (14.21)
33,257 (14.95)
10,985 (64.08)
21,133 (64.63)
Healthcare Access
Healthcare Coverage
Yes
303,125 (14.50)
407,772 (14.46)
<.0001
166,624 (56.20)
225,751 (56.33)
<.0001
No
94,210 (32.70)
90,653 (30.53)
53,169 (57.82)
50,266 (56.44)
Healthcare Providers
At least one
300,058 (14.80)
391,389 (14.31)
<.0001
169,097 (57.58)
220,773 (57.35)
<.0001
No
97,212 (26.66)
106,253 (25.26)
50,706 (53.66)
54,876 (52.73)
Socio-economic Status
Income level
< $10,000
36,174 (32.02)
41,227 (31.16)
<.0001
22,212 (62.81)
24,599 (60.78)
<.0001
$10,000 - < $20,000
76,965 (25.50)
86,079 (25.47)
45,485 (60.52)
50,089 (59.40)
$20,000 - < $50,000
151,150 (18.48)
182,850 (18.68)
82,335 (55.77)
10,611 (55.92)
≥ $50,000
88,676 (10.75)
133,184 (10.47)
46,089 (52.77)
71,597 (54.42)
Education
<High school
64,218 (27.0)
67,379 (26.58)
< .0001
37,016 (59.12)
37,967 (57.37)
< .0001
High school grad
154,172 (21.12)
190,719 (21.51)
83,566 (55.53)
103,138 (54.98)
Some college or higher
179,344 (12.70)
240,561 (12.12)
99,466 (56.63)
135,099 (57.16)
Employment
Employed
180,242 (17.60)
230,795 (16.26)
<.0001
97,836 (55.54)
126,946 (56.08)
<.0001
Self-Employed
32,272 (15.02)
38,167 (14.29)
16,554 (52.26)
19,985 (53.18)
Unemployed
34,859 (33.66)
47,899 (30.40)
20,970 (61.51)
28,317 (60.07)
Student/Homemaker/Retired
93,249 (10.60)
115,721 (10.42)
48,573 (52.84)
60,191 (52.46)
Unable to work
56,559 (33.14)
65,265 (34.51)
35,837 (64.55)
40,344 (62.78)
*Current smoker is defined as every day or someday smoker who smoked at least 100 cigarettes in their lifetime.
Quit attempts is defined as stopped smoking for one day or longer because of trying to quit smoking.
Expanded states include AK, AR, AZ, CA, CO, CT, DE, HI, IA, IL, IN, KY, MD, MA, MI, MN, NV, NH, NJ, NM, NY, ND, OH, OR, PA,
RI, VT, WA, WV, and DC which expanded Medicaid under the ACA between 2010 and 2015
Non-Expanded states did not expand Medicaid under the ACA till the end of 2015.
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Table 3: Relative risks for current smoking and quit attempts by ACA expansion status and age-group, US BRFSS
2003-2015
Current smokers (%)
Quit Attempts (%)
Year
Overall US
Expanded
Non-expanded
18-49 years
Expanded
Non-expanded
50-79 years
Expanded
Non-expanded

2003-2009*

2011-2015†

2003-2009†

2011-2015†

262,751 (17.22)
205,078 (18.28)
RR = 1.02 (1.02-1.03)

200,030 (16.07)
160,235 (15.46)
RR = 0.99 (0.99-1.00)

143,057 (55.31)
110,105 (54.59)
RR = 0.98 (0.98-0.99)

113,123 (56.86)
91,410 (57.34)
RR = 1.01 (1.01-1.02)

142,484 (21.61)
108,863 (23.19)
RR = 1.02 (1.01-1.02)

88,645 (19.79)
70,683 (20.84)
RR = 1.01 (1.01-1.02)

81,926 (58.52)
61,681 (57.86)
RR = 0.99 (0.99-1.00)

53,845 (61.14)
43,527 (61.98)
RR = 1.01 (1.01-1.02)

114,680 (15.45)
92,283 (16.45)
RR = 1.02 (1.02-1.03)

106,501 (14.68)
85,935 (15.27)
RR = 0.98 (0.98-0.99)

58,669 (52.42)
46,729 (51.76)
RR = 0.98 (0.98-0.99)

57,077 (53.83)
46,245 (54.02)
RR = 0.99 (0.99-1.00)

>=80 years
Expanded
Non-expanded

3,843 (3.87)
3,613 (3.46)
1,594 (41.74)
1,538 (42.85)
2,766 (3.79)
2,895 (3.37)
1,128 (41.05)
1,241 (43.04)
RR = 0.96 (0.96-0.97) RR = 0.99 (0.99-1.00) RR = 0.96 (0.96-0.97)
RR = 1.02 (1.02-1.03)
Reference = Expanded; RR = relative risk. RRs for age categories have been adjusted for sex, race, annual household
income, and educational status using Proc Genmod. Excluded 2010 data as the wash-out period.
* Linear trend p = 0.13; quadratic trend p < 0.0001
† Linear trend p < 0.0001

Table 4. Relative Risks for Current Smokers and Quit Attempts by Expansion and Time Period, US BRFSS 2003-2015
Low Income (≤$20,000)

Overall
Current Smoking*

Quit Attempts*

Current Smoking

Quit Attempts*

RR (95% CI)

RR (95% CI)

RR (95% CI)

RR (95% CI)

Pre-expansion (2003-2009)

Ref

Ref

Ref

Ref

Post-expansion (2011-2015)

0.94 (0.93-0.94)

1.04 (1.04-1.05)

0.99 (0.99-1.00)

1.05 (1.05-1.06)

Pre-expansion (2003-2009)

Ref

Ref

Ref

Ref

Post-expansion (2011-2015)

0.94 (0.94-0.95)

1.03 (1.02-1.03)

0.99 (0.99-1.00)

1.04 (1.04-1.05)

Expanded

Non-expanded

Note: Relative risks were adjusted for sex, race, annual household income, educational status including interaction terms for
expansion status and time periods of pre-and post-expansion using Proc Genmod. Excluded 2010 data as the wash-out period.
P-value for expand x period interaction: *<0.0001;  0.0019

Annual household income ≤ $20,000
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Table 5. Relative Risks for Quit Attempts by Expansion and Time Period by Prior Authorization, US BRFSS
2003-2015
Quit Attempts
Prior authorization
Overall
Yes
No
Expanded
RR (95% CI)
RR (95% CI)
RR (95% CI)
Pre-expansion
(2003Ref
Ref
Ref
2009)
Post-expansion (20111.04 (1.04 – 1.05)
1.03 (1.02 – 1.03)
1.06 (1.05 – 1.06)
2015)
Non-expanded
Pre-expansion
(2003Ref
Ref
Ref
2009)
Post-expansion (20111.03 (1.02 – 1.03)
1.03 (1.02 – 1.03)
1.03 (1.02 – 1.03)
2015)
Note: Relative risks were adjusted for sex, race, annual household income, educational status including interaction
terms for expansion status and time periods of pre-and post-expansion using Proc Genmod. Excluded 2010 data as
the wash-out period.
Prior authorization required for smoking cessation among states include: AK, AL, AR, CO, DE, HI, IA, ID, MA,
ME, MI, MO, MT, ND, NE, NV, OK, RI, TN, UT, VT, WA, and WV (23 states).

Table 6. Relative Risks for Quit Attempts by Expansion and Time Period by Co-payment, US BRFSS 20032015
Quit Attempts
Co-payments
Overall
Yes
No
Expanded
RR (95% CI)
RR (95% CI)
RR (95% CI)
Pre-expansion (2003Ref
Ref
Ref
2009)
Post-expansion (20111.04 (1.04 – 1.05)
1.03 (1.02 – 1.03)
1.07 (1.06 – 1.07)
2015)
Non-expanded
Pre-expansion (2003Ref
Ref
Ref
2009)
Post-expansion (20111.03 (1.02 – 1.03)
1.02 (1.02 – 1.03)
1.03 (1.03 – 1.04)
2015)
Note: Relative risks were adjusted for sex, race, annual household income, educational status including interaction
terms for expansion status and time periods of pre-and post-expansion using Proc Genmod. Excluded 2010 data as
the wash-out period.
Co-payments required for smoking cessation among states include: AK, CA, CO, DE, OA, IL, IN, KS, LA, MA,
ME, MN, MS, MT, NC, ND, NE, NH, NV, OH, OK, OR, PA, SD, TX, UT, VA, VT, WI, WV, and, WY (31 states).
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FIGURES
Figure 1: Prevalence of current smoking in the expanded vs. non-expanded states – BRFSS,
United States, 2003-2015

Figure 2: Prevalence of adult smokers reporting a quit attempt during the previous year in
the expanded vs. non-expanded states – BRFSS, United States, 2003-2015
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Supplemental Tables
Table 1: Relative Risks for Current Smoking and Quit Attempts by ACA Expansion Status by Age-Group, US
BRFSS 2011-2017
Current smokers (%)
Year
Overall US
Expanded
Non-expanded

18-49 years
Expanded
Non-expanded

50-79 years
Expanded
Non-expanded

Quit Attempts (%)

2011-2013

2015-2017

2011-2013

2015-2017

128,687 (16.37)
104,257 (16.84)
RR = 0.994
(0.994-0.995)

107,521 (14.47)
82846 (15.33)
RR = 1.016
(1.016-1.017)

72691 (57.16)
59290 (57.90)
RR = 1.006
(1.006-1.007)

59957 (56.01)
46852 (56.77)
RR = 1.011
(1.011-1.011)

59302 (20.66)
46892 (21.58)
RR = 0.996
(0.996-0.997)

45590 (18.10)
35803 (19.47)
RR = 1.035
(1.035-1.036)

35801 (61.22)
28636 (62.37)
RR = 1.015
(1.014-1.015)

27367 (60.27)
21983 (61.66)
RR = 1.023
(1.022-1.023)

67045 (15.19)
55486 (15.81)
RR = 0.992
(0.991-0.992)

59994 (13.89)
45477 (14.61)
RR = 0.997
(0.996-0.997)

35893 (53.84)
29850 (54.46)
RR = 0.997
(0.997-0.998)

31787 (53.20)
24212 (53.37)
RR = 1.0008
(1.0005-1.001)

>=80 years
Expanded
Non-expanded

2340 (3.62)
1937 (3.24)
997 (42.50)
803 (41.78)
1879 (3.42)
1566 (3.41)
804 (42.21)
657 (42.11)
RR = 1.005
RR = 1.006
RR = 0.968
RR = 0.995
(1.001-1.008)
(1.004-1.008)
(0.964-0.973)
(0.993-0.997)
Reference = Expanded; RR = rate ratio. RRs for age categories have been adjusted for sex, race, annual household income,
and education status using Proc Genmod; excluding year 2014 as the washout period.
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Table 2. Relative Risks for Current Smokers and Quit Attempts by Expansion and Time Period, US BRFSS 2011-2017
Low Income (≤$20,000)

Overall
Current smoking*

Quit Attempts*

Current Smoking*

Quit Attempts*

RR (95% CI)

RR (95% CI)

RR (95% CI)

RR (95% CI)

Pre-expansion (2011-2013)

Ref

Ref

Ref

Ref

Post-expansion (2015-2017)

0.971
(0.971-0.972)

0.995
(0.995-0.996)

0.994
(0.9932-0.9947)

0.992
(0.991-0.993)

Ref

Ref

Ref

Ref

Expand

Non-expanded
Pre-expansion (2011-2013)
Post-expansion (2015-2017)

0.946
0.991
0.977
0.982
(0.945-0.946)
(0.990-0.991)
(0.976-0.978)
(0.982-0.983)
Note: Rate ratios were adjusted for sex, race, annual household income, educational status including interaction terms for
expansion status and time periods of pre-and post-expansion using Proc Genmod
P-value for expansion x time period interaction: *<0.0001

Annual household income ≤ $20,000
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CHAPTER 4

CONCLUSION
This capstone attempted to address environmental health and health policy issues using publicly
available nationally representative data and epidemiologic methods. The purpose of this chapter
is to briefly summarize the findings from the two diverse papers, discuss the public health
implications of the two studies and to briefly summarize the limitations and recommendations.

Summary of Findings
The first paper hypothesized that increasing blood Mn levels will be associated with
higher prevalence of MI and stroke, while renal dysfunction prevalence will reduce with
increasing blood Mn levels. In our findings, we found an increasing 10% non-significant
increase of myocardial infarction and stroke. However, we did not find a significant reduction in
the prevalence of renal dysfunction with increasing blood Mn levels. There were no differences
in the association between blood Mn levels and myocardial infarction, stroke and renal
dysfunction based on poverty income ratio.
Despite the lack of significant findings, there was a non-significant increasing trend for
blood Mn levels and myocardial infarction and stroke. Due to the cross-sectional, we cannot
establish a causal relationship based on our findings. However, both the outcomes and the
exposure were measured using standard procedures from a nationally representative US
population. This association needs to be further validated in prospective cohort studies to
determine adverse effects of Mn on myocardial infarction and stroke.
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The second paper focused to evaluate the impact of the Affordable Care Act (ACA) expansion
on current smoking and quit-attempts in the expanded and the non-expanded US states, to
evaluate the impact among low-income individuals; accounting for state-level barriers to
smoking cessation services. Overall, during the pre-expansion period (2003-2009) current
smoking was 2% higher in the non-expanded states compared to the expanded states, but it was
lower 1% lower in the non-expanded states compared to the expanded states during the postexpansion period (2011-2015). However, there was a 6% decline in current smoking in both the
expanded and non-expanded states in the post- versus the pre-expansion period and a 4%
increase in the quit-attempts. Moreover, there were no significant changes in current smoking
rates among individuals with annual household incomes ≤$20,000; however, there was 4-5%
increase in the quit-attempts in the post-expansion period compared to the pre-expansion period.
Thus, following the ACA there were declines in current smoking rates both in the expanded and
non-expanded states.
The analyses from these two papers are beneficial to public health practitioners as they both
attempt to find environmental and health policies that can reduce the burden of chronic diseases
in the US.

Implications for Public Health
The role of public health is to protect and improve the health of the general population by health
promotion, policy development, and disease prevention. Therefore, public health professionals
aim to identify populations that are the most vulnerable. Since, clinical professions like doctors
and nurses focus primarily on treating illnesses on individuals, public health works to reduce
health disparities in the population. Thus, public health incorporates all aspects of an individual’s
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well-being like social and physical environment, availability of health services, health behavior,
and biology to address health issues in the population.
This capstone has attempted to identify the vulnerable and disparate populations using
epidemiologic methods to assess biology, environmental, and health policy on the prevalence of
chronic diseases and their risk factors. As practicing epidemiologists, it is our role to identify the
primary risk factors and initiate the necessary health policies that can influence the health of a
community and the general population. As we did find that certain policies help to reduce health
disparities, we need to better on reducing barriers and administrative costs for the vulnerable
populations that prevent access to timely preventive care.
The analyses of the two papers is timely as they address the environmental, biological,
and health policy impact on risk factors that are associated with the onset of chronic diseases.
Future research needs to evaluate implementation of policy and studies to prospectively assess
the biomarkers that can reduce the cost of chronic diseases in the United States.
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